Insider Selling: Omada Health (NASDAQ:OMDA) President Sells 8,866 Shares

Omada Health, Inc. (NASDAQ:OMDA) President Wei-Li Shao sold 8,866 shares of Omada Health stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $25.02, for a total transaction of $221,827.32. Following the transaction, the president directly owned 307,372 shares in the company, valued at $7,690,447.44. This trade represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Wei-Li Shao also recently made the following trade(s):

• On Friday, June 12th, Wei-Li Shao sold 4,589 shares of Omada Health stock. The shares were sold at an average price of $17.24, for a total transaction of $79,114.36.

Omada Health Stock Performance

Shares of NASDAQ OMDA traded down $0.17 during midday trading on Wednesday, reaching $23.84. 1,552,408 shares of the stock were exchanged, compared to its average volume of 1,274,695. The stock has a market capitalization of $1.46 billion, a P/E ratio of 476.80 and a beta of 1.73. The company has a 50 day simple moving average of $20.61 and a 200 day simple moving average of $16.32. Omada Health, Inc. has a twelve month low of $10.28 and a twelve month high of $26.92.

Omada Health (NASDAQ:OMDA) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.10. The firm had revenue of $87.83 million for the quarter, compared to analysts’ expectations of $80.93 million. Omada Health had a return on equity of 2.67% and a net margin of 1.39%. On average, research analysts expect that Omada Health, Inc. will post -0.01 earnings per share for the current year.

Trending Headlines about Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Omada’s second-quarter results provided further evidence that revenue growth is translating into profitability. The company reported earnings of $0.08 per share versus a consensus loss of $0.02 and revenue of approximately $87.8 million, well above the $80.9 million analyst estimate. The results support the bullish case for Omada’s digital chronic-care platform and improving financial execution. Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings
• Positive Sentiment: Robert W. Baird raised its price target on OMDA from $15 to $25, reflecting improved expectations following the earnings performance. However, the firm maintained a neutral rating, indicating that much of the near-term upside may already be reflected in the stock price. Benzinga analyst update
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with a reported consensus rating of “Moderate Buy” and an average price target of $25.67. Recent targets range from $24 to $35, but the wide range highlights uncertainty around valuation and future growth.
• Neutral Sentiment: Reported short interest was zero shares, offering no meaningful indication of short-selling pressure or potential short-covering demand.
• Negative Sentiment: CEO Sean Duffy disclosed sales of 8,628 shares at an average price of $21.85 and 12,942 shares at $24.81. The transactions reduced his direct ownership by roughly 5% across the reported sales and may weigh on sentiment, although he still owns more than 411,000 shares.
• Negative Sentiment: At roughly $24 per share, OMDA trades at a very high price-to-earnings ratio near 480, leaving the stock sensitive to disappointment in growth, margins or future earnings. Its recent performance has already placed it well above its 50-day and 200-day moving averages.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in OMDA. Quantbot Technologies LP acquired a new stake in shares of Omada Health during the 2nd quarter worth about $1,695,000. Ieq Capital LLC acquired a new position in Omada Health in the second quarter valued at approximately $1,728,000. AlpInvest Partners B.V. purchased a new position in Omada Health in the second quarter valued at approximately $1,182,000. BlackRock Inc. purchased a new position in Omada Health in the second quarter valued at approximately $48,775,000. Finally, Deutsche Bank AG acquired a new stake in Omada Health during the second quarter worth approximately $777,000.

Analyst Ratings Changes

OMDA has been the subject of a number of research analyst reports. The Goldman Sachs Group reiterated a “buy” rating on shares of Omada Health in a report on Friday, May 8th. Barclays boosted their price objective on shares of Omada Health from $20.00 to $25.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. BTIG Research upped their target price on shares of Omada Health from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Monday. Wells Fargo & Company increased their target price on shares of Omada Health from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Finally, Evercore reiterated an “outperform” rating and set a $20.00 price target on shares of Omada Health in a research report on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $25.75.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.